GlassScriptPhysician profile
John Thomas Kolisnyk
NPI 1457444994
$8,463.84
in general payments reported to CMS, 2019-2025
28 companies · $1,777 in 2025
The $1,777 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $702 · 2021: $861 · 2022: $1,421 · 2023: $1,061 · 2024: $2,028 · 2025: $1,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,767 · Education: $56.01 · Consulting Fee: $42.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,767.45 |
| Education | $56.01 |
| Consulting Fee | $42.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,042.55 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,246.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $643.90 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $618.78 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $528.88 | 2020-2025 | Cuvitru, Hyqvia |
| Novartis Pharmaceuticals Corporation | $494.87 | 2019-2025 | |
| Pfizer INC. | $422.06 | 2019-2025 | |
| Csl Behring | $367.41 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Amgen INC. | $342.26 | 2022-2025 | Tezspire |
| Optinose US, INC. | $277.78 | 2021-2025 | |
| Genentech USA, INC. | $229.54 | 2022-2025 | Xolair |
| Kaleo, INC. | $206.65 | 2019-2023 | Auvi-Q |
| Grifols USA, LLC | $171.94 | 2022-2025 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.10 | 2019-2022 | |
| Alk-Abello, INC | $128.45 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $123.73 | 2021-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $114.72 | 2025 | Neffy |
| Octapharma USA, INC. | $105.40 | 2021-2025 | Cutaquig |
| Merck Sharp & Dohme LLC | $44.78 | 2021-2023 | |
| Adma Biomanufacturing LLC | $42.71 | 2025 | |
| Lilly USA, LLC | $32.92 | 2025 | Ebglyss |
| Aimmune Therapeutics, INC. | $23.44 | 2021 | |
| Cycle Pharmaceuticals INC | $17.80 | 2025 | Sajazir |
| Jubilant Hollisterstier LLC | $17.09 | 2023 | |
| Hikma Pharmaceuticals USA | $16.06 | 2025 | Ryaltris |
| Blueprint Medicines Corporation | $16.00 | 2022 | |
| Mylan Specialty L.P. | $13.10 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kolisnyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.